Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

Free Research Reports on ARNA, GPOR, SWHC and VNDA Issued by the Bedford Report Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT


Print article Print article
© Marketwire 2012
2012-12-19 14:25:04 -

NEW YORK, NY -- (Marketwire) -- 12/19/12 -- The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.



Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares of the anti-obesity drug maker have gained over 400 percent year-to-date. The company last month entered into a co-development and license agreement with Ildong Pharmaceutical Co., Ltd., for temanogrel, a novel agent for thrombotic diseases.





Find out more about Arena Pharmaceuticals including full access to the free equity report at: www.BedfordReport.com/ARNA : www.bedfordreport.com/ARNA



Gulfport Energy Corporation (NASDAQ: GPOR) shares of the oil & gas company have gained over 33 percent year-to-date. The company has recently entered into a definitive agreement to purchase approximately 30,000 net acres in the Utica Shale.



Find out more about Gulfport Energy including full access to the free equity report at: www.BedfordReport.com/GPOR : www.bedfordreport.com/GPOR



Smith & Wesson Holding Corp. (NASDAQ: SWHC) shares of the gun maker fell 10 percent on more than 22 million shares traded Tuesday. Pressure to tighten the nation's gun laws has increased following the shooting at Sandy Hook elementary school in Connecticut.



Find out more about Smith & Wesson including full access to the free equity report at: www.BedfordReport.com/SWHC : www.bedfordreport.com/SWHC



Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) shares soared nearly 20 percent on over 4.5 million shares traded Tuesday after reporting positive results from a Phase III study of tasimelteon, a circadian regulator for the treatment of Non-24-Hour Disorder.



Find out more about Vanda Pharmaceuticals including full access to the free equity report at: www.BedfordReport.com/VNDA : www.bedfordreport.com/VNDA



Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein.



A third party, Providence Media Strategies LLC has paid Equity News Circuit four hundred and fifty dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.




Contact Information:

Equity News Circuit
Email Contact : www2.marketwire.com/mw/emailprcntct?id=AFC6D54569C309F8



Press Information:




Contact Person:


Disclaimer: (c) 2014 Market Wire. All of the press releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Market Wire's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com | BidVertiser